Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2208 - A prospective study about the complementary medicine among patients with cancers

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Wala Ben Kridis

Citation

Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265

Authors

W. Ben Kridis, A. Mnif, A. Khanfir

Author affiliations

  • Medical Oncology Department, University of Sfax - Hopital Habib Bourguiba, 3089 - Sfax/TN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2208

Background

There is limited information on the association among complementary medicin (CM), toxicities and overall survival of patients with cancer who receive CM compared with those who do not.

Methods

This is a prospective study including 223 patients collected during 6 months between July 15, 2018 and January 15, 2019 in the department of medical oncology at the Habib Bourguiba university Hospital. All patients were questioned about the concept of taking herbs and botanicals such as gravila and Alinda. We analyzed the demographic data, the toxicities after the consumption of plants as well as the causal link. Then we compared overall survival among those who receive plants versus the non-users.

Results

The average age was 53 years (2-86 years old). There were 152 women and 71 men. 83 patients were illiterate (37.2%). 110 patients had breast cancer (49.3%), the others included colorectal, endometrial, cervical, gastric, ovarian, lung, bladder and head and neck cancers). 97 had metastatic disease (43.4%). 97 patients had taken plants (43.4%), during the medical treatment in 57 cases (58.7%). 60 patients had consumed Alinda (61.8%) and 36 patients had received Graviola (37.1%). 62 women had taken plants against 37 men (χ2 = 1.425, ddl = 1, α = 5%, p = 0.147). 49 patients with metastatic disease had taken plants against 48 with localized cancer (χ2 = 3.468, ddl = 2, α = 5%, p = 0.177). 10 patients have had diarrhea (10.3%), 10 cytolysis (10.3%), 11 cholestasis (11.3%), 15 thrombocytosis (15.4%), 17 leukocytosis (17.5%) and 13 anemia (13.4%). Only leukocytosis, thrombocytosis, and diarrhea were related to plant consumption with p = 0.0001, p = 0.016 and p = 0.014 respectively. Overall survival at 5 years was 67.1%. It was lower in patients consuming the plants (54% vs 83% p = 0.023).

Conclusions

The consumption of Graviola and Alinda was associated with a decrease in the 5 years overall survival (p = 0.023). It was associated with leukocytosis, thrombocytosis, and diarrhoea. This consumption was not statistically different between men and women nor between the localized or metastatic stage.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.